Gregory M Pastores1. 1. New York University School of Medicine, 403 East 34th Street, 2nd Floor, New York, NY 10016, USA. gregory.pastores@med.nyu.edu
Abstract
BACKGROUND: Laronidase (Aldurazyme) is a recombinant formulation of alpha-L-iduronidase, the enzyme deficient in mucopolysaccharidosis type I (MPS-I); a disorder associated with skeletal dysplasia, restricted joint movement, short stature, obstructive pulmonary disease, cardiac valvular problems and cognitive impairment (in the severe and intermediate variants). OBJECTIVE: To describe MPS-I and review data on the safety and efficacy of laronidase. RESULTS: Laronidase is safe and effective in stabilizing or improving pulmonary function and physical endurance. As intravenously administered enzyme is unable to correct CNS disease, hematopoietic stem cell transplantation remains the primary treatment for Hurler's syndrome despite the morbidity and mortality risks. CONCLUSIONS: Palliative care remains part of the treatment. Long-term studies are required to ascertain the effect of enzyme therapy on survival and its effectiveness in modifying the disease course and reducing morbidity. Intrathecal administration is under investigation for patients with signs of cord compression secondary to glycosaminoglycan accumulation within the dura matter. The cost of therapy remains a concern.
BACKGROUND: Laronidase (Aldurazyme) is a recombinant formulation of alpha-L-iduronidase, the enzyme deficient in mucopolysaccharidosis type I (MPS-I); a disorder associated with skeletal dysplasia, restricted joint movement, short stature, obstructive pulmonary disease, cardiac valvular problems and cognitive impairment (in the severe and intermediate variants). OBJECTIVE: To describe MPS-I and review data on the safety and efficacy of laronidase. RESULTS: Laronidase is safe and effective in stabilizing or improving pulmonary function and physical endurance. As intravenously administered enzyme is unable to correct CNS disease, hematopoietic stem cell transplantation remains the primary treatment for Hurler's syndrome despite the morbidity and mortality risks. CONCLUSIONS: Palliative care remains part of the treatment. Long-term studies are required to ascertain the effect of enzyme therapy on survival and its effectiveness in modifying the disease course and reducing morbidity. Intrathecal administration is under investigation for patients with signs of cord compression secondary to glycosaminoglycan accumulation within the dura matter. The cost of therapy remains a concern.
Authors: Daren Wang; Salim S El-Amouri; Mei Dai; Chia-Yi Kuan; David Y Hui; Roscoe O Brady; Dao Pan Journal: Proc Natl Acad Sci U S A Date: 2013-02-04 Impact factor: 11.205
Authors: L Borgwardt; C I Dali; J Fogh; J E Månsson; K J Olsen; H C Beck; K G Nielsen; L H Nielsen; S O E Olsen; H M F Riise Stensland; O Nilssen; F Wibrand; A M Thuesen; T Pearl; U Haugsted; P Saftig; J Blanz; S A Jones; A Tylki-Szymanska; N Guffon-Fouiloux; M Beck; A M Lund Journal: J Inherit Metab Dis Date: 2013-03-14 Impact factor: 4.982
Authors: Natalie S Rodriguez; Lisa Yanuaria; Kevin Murphy R Parducho; Irving M Garcia; Bino A Varghese; Brendan H Grubbs; Toshio Miki Journal: Stem Cells Transl Med Date: 2017-06-06 Impact factor: 6.940